Interleukin-6 inhibition in the treatment of autoinflammatory diseases.

Szczegóły
Abstrakt

Tytuł:: Interleukin-6 inhibition in the treatment of autoinflammatory diseases.
Autorzy:: Koga T; Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kawakami A; Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Źródło:: Frontiers in immunology [Front Immunol] 2022 Jul 26; Vol. 13, pp. 956795. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:: Cryopyrin-Associated Periodic Syndromes*/drug therapy
Familial Mediterranean Fever*/drug therapy
Hereditary Autoinflammatory Diseases*/drug therapy
Humans ; Inflammasomes ; Interleukin-6
References:: Crit Care Med. 2017 Feb;45(2):e124-e131. (PMID: 27632680)
Am J Epidemiol. 2012 May 15;175(10):1054-61. (PMID: 22234484)
Stem Cells. 1994 May;12(3):262-77. (PMID: 8075593)
J Interferon Cytokine Res. 1998 Jul;18(7):479-83. (PMID: 9712363)
Immunol Med. 2018 Jun;41(2):55-61. (PMID: 30938266)
Rheumatology (Oxford). 2015 Mar;54(3):564-5. (PMID: 25504961)
Front Immunol. 2021 Nov 11;12:744780. (PMID: 34858402)
Ann Intern Med. 1977 Feb;86(2):162-5. (PMID: 319724)
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S1-3. (PMID: 19796522)
PLoS One. 2011;6(5):e20014. (PMID: 21637346)
N Engl J Med. 1972 Dec 21;287(25):1302. (PMID: 4636899)
Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl 127(5):76-79. (PMID: 33200741)
Mod Rheumatol. 2016 Jul;26(4):610-3. (PMID: 25619282)
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):596-609. (PMID: 29773275)
Lancet. 2008 Mar 22;371(9617):987-97. (PMID: 18358926)
Intern Med. 2015;54(16):2069-72. (PMID: 26278305)
Hematology Am Soc Hematol Educ Program. 2005;:74-81. (PMID: 16304362)
J Exp Med. 2015 Jun 1;212(6):927-38. (PMID: 26008898)
Eur J Rheumatol. 2015 Mar;2(1):35-36. (PMID: 27708919)
Blood. 2021 Jul 1;137(26):3682-3684. (PMID: 33619558)
N Engl J Med. 2020 Dec 31;383(27):2628-2638. (PMID: 33108101)
N Engl J Med. 2017 Jul 27;377(4):317-328. (PMID: 28745999)
Front Immunol. 2021 Feb 01;11:619257. (PMID: 33603750)
Immunol Med. 2018 Dec;41(4):177-180. (PMID: 30714492)
Ann Rheum Dis. 2021 Nov;80(11):1501-1502. (PMID: 34260381)
J Clin Rheumatol. 2014 Mar;20(2):103-5. (PMID: 24561416)
Medicine (Baltimore). 2016 Apr;95(16):e3449. (PMID: 27100444)
Mod Rheumatol. 2016 Sep;26(5):637-41. (PMID: 26939747)
Blood. 1995 Aug 15;86(4):1243-54. (PMID: 7632928)
Lancet Respir Med. 2021 May;9(5):511-521. (PMID: 33676589)
J Exp Med. 2004 Sep 6;200(5):551-8. (PMID: 15353551)
J Clin Rheumatol. 2021 Apr 1;27(3):e95. (PMID: 31972736)
Rheumatology (Oxford). 2006 Jan;45(1):31-7. (PMID: 16287931)
Mod Rheumatol. 2021 Jan;31(1):223-225. (PMID: 31903820)
Eur J Pediatr. 1989 Jun;148(7):636-41. (PMID: 2663516)
Ann Rheum Dis. 2018 Mar;77(3):348-354. (PMID: 29191819)
Clin Exp Rheumatol. 2004 Jul-Aug;22(4 Suppl 34):S34-6. (PMID: 15515781)
Lancet. 1998 Feb 28;351(9103):659-64. (PMID: 9500348)
Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):150-1. (PMID: 24064027)
Clin Rheumatol. 2004 Aug;23(4):333-7. (PMID: 15293095)
Ann Rheum Dis. 2018 Dec;77(12):1720-1729. (PMID: 30279267)
Biochem Biophys Res Commun. 2004 Feb 6;314(2):363-9. (PMID: 14733913)
Cell. 1999 Apr 2;97(1):133-44. (PMID: 10199409)
Hematol Oncol Clin North Am. 2018 Feb;32(1):23-36. (PMID: 29157617)
Semin Arthritis Rheum. 2013 Dec;43(3):387-91. (PMID: 23742958)
Nefrologia. 2016;36(1):63-6. (PMID: 26409501)
Arthritis Rheum. 2011 Apr;63(4):1151-5. (PMID: 21225679)
Mod Rheumatol. 2019 Mar;29(2):302-305. (PMID: 30285516)
Ann Rheum Dis. 2016 Apr;75(4):644-51. (PMID: 26802180)
Mod Rheumatol. 2021 May;31(3):762-763. (PMID: 32701042)
Int J Rheum Dis. 2017 Nov;20(11):1868-1871. (PMID: 26481326)
Contributed Indexing:: Keywords: amyloidosis; autoinflammatory diseases; familial mediterranean fever; inflammasome; interleukin-6
Substance Nomenclature:: 0 (Inflammasomes)
0 (Interleukin-6)
Entry Date(s):: Date Created: 20220812 Date Completed: 20220815 Latest Revision: 20220825
Update Code:: 20240104
PubMed Central ID:: PMC9360993
DOI:: 10.3389/fimmu.2022.956795
PMID:: 35958618
: Czasopismo naukowe

Full Text Finder

Autoinflammatory diseases are characterized by abnormalities that prevent innate immune cells from producing autoantibodies. While interleukin (IL)-6 is not directly associated with inflammasomes, like IL-1β or IL-18, it plays an important role in the pathogenesis of autoinflammatory diseases. Studies of autoinflammatory diseases, such as familial Mediterranean fever, cryopyrin-associated periodic syndrome, and tumor necrosis factor receptor-associated periodic syndrome, have shown IL-6 to be a promising therapeutic target. It has also been suggested that inhibition of IL-6 may have a therapeutic effect on amyloidosis, which is frequently associated with these chronic inflammatory diseases. In this study, we discuss the most recent research on the role of IL-6 in autoinflammatory diseases and its potential as a therapeutic target in their treatment.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Koga and Kawakami.)

Informacja